Trk-INHIBITING COMPOUND

摘要

The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.;

主权项

1. A compound represented by the general formula I): wherein: a ring Cy1 represents a C3-10 monocyclic carbocycle or bicyclic carbocycle or a 4- to 10-membered monocyclic heterocycle or bicyclic heterocycle; a ring Cy2 represents a 4- to 10-membered monocyclic heterocycle or bicyclic heterocycle excluding a heterocycle 1,3-thiazol-5-yl group; R1 represents: (1) a halogen; (2) a C1-6 alkyl group, C2-6 alkenyl group or C2-6 alkynyl group optionally substituted with a substituent selected from the group consisting of (i) a halogen and (ii) a hydroxy group; (3) a C5-6 monocyclic carbocycle optionally substituted with one or two R5 groups; (4) a 5- to 6-membered monocyclic heterocycle optionally substituted with one or two R5 groups; (5) —S(O)m1—R6; (6) —SO2NR7R8; (7) —C(O)OR9; (8) —NR10C(O)R11; (9) —C(O)NR12R13; (10) —OR14; (11) —NR15R16; (12) a cyano group; or (13) a nitro group; R5 represents: (1) a halogen; (2) —S(O)m2—R17; (3) —SO2NR18R19; (4) —C(O)OR20; (5) —NR21C(O)R22; (6) —C(O)NR23R24; (7) —OR25; (8) —NR26R27; (9) a cyano group; (10) a nitro group; or (11) a C1-3 alkyl group optionally substituted with a substituent selected from the group consisting of (i) a halogen, (ii) a hydroxy group and (iii) an oxo group; when two R5 groups are present, the R5 groups may be independently the same or different; when, further, two R5 groups are respectively and independently a C1-3 alkyl group or a hydroxy group and the R5 groups are attached to carbon atoms adjacent to each other on the C5-6 monocyclic carbocycle or the 5- to 6-membered monocyclic heterocycle, the R5 groups may together form a ring; R6 to R27 respectively and independently represent (1) a hydrogen atom or (2) a C1-6 alkyl group optionally substituted with (i) a halogen or (ii) a hydroxy group; when R18 and R19 are respectively and independently a C1-6 alkyl group, R18 and R19 groups may together form a ring; R2 represents: (1) a halogen; (2) a C1-6 alkyl group optionally substituted with (i) a halogen or (ii) a hydroxy group; (3) a C3-6 cycloalkyl group optionally substituted with (i) a halogen or (ii) a hydroxy group; (4) a C1-6 alkoxy group optionally substituted with a halogen; (5) —NR28R29; (6) a 3- to 7-membered monocyclic heterocycle; or (7) —O-(3- to 7-membered monocyclic heterocycle); R28 and R29 respectively and independently represent (1) a hydrogen atom or (2) a C1-6 alkyl group optionally substituted with (i) a halogen or (ii) a hydroxy group; A1 and A2 respectively and independently represent ═CR3— or ═N—; A3, A4, A5 and A6 respectively and independently represent ═CR4— or ═N—; R3 and R4 respectively and independently represent a hydrogen atom or a halogen; m1 represents an integer of 0 to 2; m2 represents an integer of 0 to 2; p represents an integer of 0 to 7; q represents an integer of 0 to 7; r represents an integer of 0 to 2; provided that when p, q and r respectively represent an integer of 2 or more, R1, R2 and R3 groups may be respectively and independently the same or different, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof.